
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4A5A48AF2307305A5A4000CF7CC26.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="sigtrans">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Signal Transduction and Targeted Therapy">
<meta name="citation_title" content="A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol">
<meta name="citation_author" content="Lixian Chang">
<meta name="citation_author_institution" content="State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China">
<meta name="citation_author_institution" content="Tianjin Institutes of Health Science, Tianjin, China">
<meta name="citation_author" content="Ju Gao">
<meta name="citation_author_institution" content="West China Second University Hospital, Sichuan University, Chengdu, China">
<meta name="citation_author" content="Xiaoying Lei">
<meta name="citation_author_institution" content="Children’s Hospital of Chongqing Medical University, Chongqing, China">
<meta name="citation_author" content="Yingyi He">
<meta name="citation_author_institution" content="Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China">
<meta name="citation_author" content="Shuquan Zhuang">
<meta name="citation_author_institution" content="Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China">
<meta name="citation_author" content="Chunhuai Li">
<meta name="citation_author_institution" content="Department of Pediatric Hematology, Children’s Medical Center, The First Hospital of Jilin University, Changchun, China">
<meta name="citation_author" content="Kaizhi Weng">
<meta name="citation_author_institution" content="Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China">
<meta name="citation_author" content="Lingzhen Wang">
<meta name="citation_author_institution" content="The affiliated hospital of Qingdao University, Qingdao, China">
<meta name="citation_author" content="Xia Guo">
<meta name="citation_author_institution" content="West China Second University Hospital, Sichuan University, Chengdu, China">
<meta name="citation_author" content="Qihui Liu">
<meta name="citation_author_institution" content="Children’s Hospital of Chongqing Medical University, Chongqing, China">
<meta name="citation_author" content="Pengfei Wang">
<meta name="citation_author_institution" content="Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China">
<meta name="citation_author" content="Yong Zhuang">
<meta name="citation_author_institution" content="Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China">
<meta name="citation_author" content="Mei Yan">
<meta name="citation_author_institution" content="The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China">
<meta name="citation_author" content="Wei Liu">
<meta name="citation_author_institution" content="Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou, China">
<meta name="citation_author" content="Hui Chen">
<meta name="citation_author_institution" content="Tianjin Children’s Hospital, Tianjin, China">
<meta name="citation_author" content="Min Zhang">
<meta name="citation_author_institution" content="Northwest women’s and children’s Hospital, Xi’an, China">
<meta name="citation_author" content="Shuhong Shen">
<meta name="citation_author_institution" content="Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp; Oncology, Shanghai, China">
<meta name="citation_author" content="Xiaofan Zhu">
<meta name="citation_author_institution" content="State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China">
<meta name="citation_author_institution" content="Tianjin Institutes of Health Science, Tianjin, China">
<meta name="citation_author" content="Xiuli Ju">
<meta name="citation_author_institution" content="Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China">
<meta name="citation_author" content="Li Zhang">
<meta name="citation_author_institution" content="State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China">
<meta name="citation_author_institution" content="Tianjin Institutes of Health Science, Tianjin, China">
<meta name="citation_author" content="Zhuo Wang">
<meta name="citation_author_institution" content="Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp; Oncology, Shanghai, China">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="10">
<meta name="citation_firstpage" content="267">
<meta name="citation_doi" content="10.1038/s41392-025-02353-1">
<meta name="citation_pmid" content="40841430">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/pdf/41392_2025_Article_2353.pdf">
<meta name="description" content="The Realgar-Indigo Naturalis formula (RIF) is a proprietary Chinese medicine, which is one of the important drugs in the treatment of pediatric acute promyelocytic leukemia (APL). However, the dose of RIF in clinical application is not uniform and ...">
<meta name="og:title" content="A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The Realgar-Indigo Naturalis formula (RIF) is a proprietary Chinese medicine, which is one of the important drugs in the treatment of pediatric acute promyelocytic leukemia (APL). However, the dose of RIF in clinical application is not uniform and ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12370879">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41392-025-02353-1"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41392_2025_Article_2353.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370879%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12370879/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12370879/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-sigtrans.jpg" alt="Signal Transduction and Targeted Therapy logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Signal Transduction and Targeted Therapy" title="Link to Signal Transduction and Targeted Therapy" shape="default" href="https://www.nature.com/sigtrans/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Signal Transduct Target Ther</button></div>. 2025 Aug 22;10:267. doi: <a href="https://doi.org/10.1038/s41392-025-02353-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41392-025-02353-1</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Signal%20Transduct%20Target%20Ther%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Lixian Chang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Lixian Chang</span></h3>
<div class="p">
<sup>1</sup>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China </div>
<div class="p">
<sup>2</sup>Tianjin Institutes of Health Science, Tianjin, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lixian Chang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ju Gao</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ju Gao</span></h3>
<div class="p">
<sup>3</sup>West China Second University Hospital, Sichuan University, Chengdu, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Ju Gao</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lei%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Xiaoying Lei</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Xiaoying Lei</span></h3>
<div class="p">
<sup>4</sup>Children’s Hospital of Chongqing Medical University, Chongqing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lei%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoying Lei</span></a>
</div>
</div>
<sup>4,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Yingyi He</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Yingyi He</span></h3>
<div class="p">
<sup>5</sup>Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yingyi He</span></a>
</div>
</div>
<sup>5,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhuang%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Shuquan Zhuang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Shuquan Zhuang</span></h3>
<div class="p">
<sup>6</sup>Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhuang%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuquan Zhuang</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Chunhuai Li</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Chunhuai Li</span></h3>
<div class="p">
<sup>7</sup>Department of Pediatric Hematology, Children’s Medical Center, The First Hospital of Jilin University, Changchun, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chunhuai Li</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weng%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Kaizhi Weng</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Kaizhi Weng</span></h3>
<div class="p">
<sup>8</sup>Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weng%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kaizhi Weng</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Lingzhen Wang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Lingzhen Wang</span></h3>
<div class="p">
<sup>9</sup>The affiliated hospital of Qingdao University, Qingdao, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lingzhen Wang</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Xia Guo</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Xia Guo</span></h3>
<div class="p">
<sup>3</sup>West China Second University Hospital, Sichuan University, Chengdu, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xia Guo</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Qihui Liu</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Qihui Liu</span></h3>
<div class="p">
<sup>4</sup>Children’s Hospital of Chongqing Medical University, Chongqing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qihui Liu</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Pengfei Wang</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Pengfei Wang</span></h3>
<div class="p">
<sup>5</sup>Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pengfei Wang</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhuang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Yong Zhuang</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Yong Zhuang</span></h3>
<div class="p">
<sup>10</sup>Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhuang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yong Zhuang</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yan%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Mei Yan</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Mei Yan</span></h3>
<div class="p">
<sup>11</sup>The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yan%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mei Yan</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Wei Liu</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Wei Liu</span></h3>
<div class="p">
<sup>12</sup>Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wei Liu</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Hui Chen</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Hui Chen</span></h3>
<div class="p">
<sup>13</sup>Tianjin Children’s Hospital, Tianjin, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hui Chen</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Min Zhang</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Min Zhang</span></h3>
<div class="p">
<sup>14</sup>Northwest women’s and children’s Hospital, Xi’an, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Min Zhang</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Shuhong Shen</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Shuhong Shen</span></h3>
<div class="p">
<sup>15</sup>Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp; Oncology, Shanghai, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuhong Shen</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Xiaofan Zhu</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Xiaofan Zhu</span></h3>
<div class="p">
<sup>1</sup>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China </div>
<div class="p">
<sup>2</sup>Tianjin Institutes of Health Science, Tianjin, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaofan Zhu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ju%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Xiuli Ju</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Xiuli Ju</span></h3>
<div class="p">
<sup>10</sup>Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ju%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiuli Ju</span></a>
</div>
</div>
<sup>10,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Li Zhang</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Li Zhang</span></h3>
<div class="p">
<sup>1</sup>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China </div>
<div class="p">
<sup>2</sup>Tianjin Institutes of Health Science, Tianjin, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Li Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Zhuo Wang</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Zhuo Wang</span></h3>
<div class="p">
<sup>15</sup>Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp; Oncology, Shanghai, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhuo Wang</span></a>
</div>
</div>
<sup>15,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China </div>
<div id="Aff2">
<sup>2</sup>Tianjin Institutes of Health Science, Tianjin, China </div>
<div id="Aff3">
<sup>3</sup>West China Second University Hospital, Sichuan University, Chengdu, China </div>
<div id="Aff4">
<sup>4</sup>Children’s Hospital of Chongqing Medical University, Chongqing, China </div>
<div id="Aff5">
<sup>5</sup>Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China </div>
<div id="Aff6">
<sup>6</sup>Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China </div>
<div id="Aff7">
<sup>7</sup>Department of Pediatric Hematology, Children’s Medical Center, The First Hospital of Jilin University, Changchun, China </div>
<div id="Aff8">
<sup>8</sup>Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China </div>
<div id="Aff9">
<sup>9</sup>The affiliated hospital of Qingdao University, Qingdao, China </div>
<div id="Aff10">
<sup>10</sup>Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China </div>
<div id="Aff11">
<sup>11</sup>The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China </div>
<div id="Aff12">
<sup>12</sup>Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou, China </div>
<div id="Aff13">
<sup>13</sup>Tianjin Children’s Hospital, Tianjin, China </div>
<div id="Aff14">
<sup>14</sup>Northwest women’s and children’s Hospital, Xi’an, China </div>
<div id="Aff15">
<sup>15</sup>Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp; Oncology, Shanghai, China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Dec 2; Revised 2025 Jun 2; Accepted 2025 Jul 13; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12370879  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40841430/" class="usa-link">40841430</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">The Realgar-Indigo Naturalis formula (RIF) is a proprietary Chinese medicine, which is one of the important drugs in the treatment of pediatric acute promyelocytic leukemia (APL). However, the dose of RIF in clinical application is not uniform and the long-term effectiveness and safety of combining RIF with all-trans retinoic acid (ATRA) in a larger population of pediatric APL patients remains undocumented. We conducted a multicenter single-arm clinical trial (ChiCTR-OIC-16010014) in China. Individuals newly diagnosed with APL were treated with CCCG-APL-2017 protocol which is based on RIF and ATRA in consolidation. The event-free survival (EFS) and overall survival (OS) outcomes were evaluated. We recruited 200 patients diagnosed with APL. The six-year OS rate was 100% in the low-risk (LR) group and 97.6% in the high-risk (HR) group. The six-year EFS rate was 98.3% in the LR group and 97.6% in the HR group. Plasma levels of arsenic remained stable after the administration of RIF at a dosage of 60 mg/kg/d for seven days and returned to baseline levels within fourteen days after discontinuation of RIF administration, which is consistent with a concentration of 135 mg/d/kg. Furthermore, controlling white blood cells (WBC) to maintain levels at or below 30 × 10<sup>9</sup>/L during induction therapy can decrease the incidence of induced differentiation syndrome (DS) or alleviate its symptoms. Our study demonstrated that the CCCG-APL-2017 protocol, which combines RIF with ATRA, is both effective and safe in treating children with APL.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Haematological cancer, Haematological cancer</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia, is characterized at the molecular level by the presence of the fusion gene of <em>PML</em> (promyelocytic leukemia) and <em>RARA</em> (retinoic acid receptor alpha), which arises from the t(15;17)(q24;q21) chromosomal translocation.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup> This cytogenetic abnormality leads to the production of an oncogenic fusion protein that disrupts the critical pathways regulating myeloid cell differentiation, particularly by inhibiting the normal transcriptional activity of <em>RARA</em>-targeted genes. Consequently, there is an abnormal accumulation of immature promyelocytes within the bone marrow, which disrupts the normal hematopoietic process and leads to the clinical manifestations of the disease.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup> Both genetic predispositions and certain environmental exposures, such as exposure to carcinogenic substances or ionizing radiation, have been identified as potential risk factors that may elevate the likelihood of developing APL.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup> Clinically, APL is noted for its rapid onset and pronounced hemorrhagic tendencies, manifesting as skin ecchymosis, epistaxis, and visceral hemorrhage. The disease is also associated with complications such as disseminated intravascular coagulation (DIC) and thrombosis, contributing to a high early mortality rate.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup> Historically, APL was among the most lethal forms of leukemia. However, the advent of treatments such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed it into a curable malignancy.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup> The rate of complete remission for APL ranges from 90 to 100%.<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup> Differentiation syndrome (DS), a prevalent complication associated with ATRA and ATO therapy, is presently understood to result from the induction of cytokine release by myeloid cells, the upregulation of cell-surface integrins, and the enhancement of myeloid cell adhesion to the vascular endothelium by ATRA and ATO. These processes contribute to increased vascular permeability and the release of inflammatory mediators and cytokines, culminating in excessive inflammation and consequent tissue damage.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup></p>
<p id="Par3">The Realgar-Indigo Naturalis Formula (RIF), alternatively designated as the “compound Huangdai tablet”, represents a clinically validated Chinese patent medicine whose therapeutic composition integrates four principal botanical constituents (Ore Realgar, Indigo Naturalis, Salvia Miltiorrhiza, and Radix Pseudostellariae).<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup> Developed in the 1980s, this pharmacologic formulation strategically employs Ore Realgar as its primary active agent, with the adjunctive components—Indigo Naturalis, Salvia Miltiorrhiza, and Radix Pseudostellariae—functioning to synergistically potentiate realgar’s therapeutic index.<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup> Contemporary clinical investigations have substantiated that RIF, when administered concomitantly with ATRA or conventional chemotherapeutic agents, achieves non-inferior efficacy outcomes compared to ATO protocols.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> Beyond comparable antileukemic activity, RIF-based regimens demonstrate distinct pharmacoeconomic advantages, including demonstrably reduced treatment-related expenditures and significantly abbreviated hospitalization durations relative to ATO-containing therapies.<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup> Furthermore, RIF has been demonstrated to have a considerably lesser impact on liver function than ATO.<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup> Despite these well-documented benefits, the existing body of research remains disproportionately focused on adult patients with acute promyelocytic leukemia, creating a significant evidence gap regarding its application in pediatric populations. Additionally, there is considerable variability across different treatment protocols regarding the optimal oral dosing parameters and the required duration of maintenance therapy for RIF, which highlights the need for further standardized clinical studies.</p>
<p id="Par4">In the consolidation therapy phase of the CCLG (Chinese children leukemia group)-APL-2016 protocol, the oral dose of RIF is specified as 60 mg/kg/d, and it is administered for a duration of 14 days.<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> In the clinical protocol described by Luo and colleagues, the oral dose of RIF was increased to 135 mg/kg per day, and the duration of oral administration was extended to 15 days during the consolidation phase.<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> In SCCLG (south China children leukemia group)-APL protocol, RIF was administered orally at a dose of 135 mg/kg per day, achieving a concentration of 0.61 μmol/L for arsenic on day 14.<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> To determine a more suitable dosage and application time of RIF in pediatric patients with APL, we previously conducted a study evaluating the pharmacokinetics and safety of oral RIF in pediatric APL patients. The findings indicated that a dosage of 60 mg/kg per day resulted in a higher steady-state trough concentration in children than that achieved in adults.<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup> However, the question of how much RIF should be used and for how long in pediatric patients still requires further exploration. Given that the induction of differentiation syndrome is a primary adverse reaction to initial therapy in patients with APL, it is crucial to address the occurrence and management of this syndrome. This represents a significant clinical concern that demands careful consideration and attention from healthcare providers.</p>
<p id="Par5">In the present study, we conducted a single-arm clinical study (ChiCTR-OIC-16010014) across multiple centers in China, based on the CCCG-APL-2017 protocol. This study was designed to optimize oral chemotherapy protocols and to comprehensively analyze efficacy, long-term survival rate, and adverse reactions associated with the use of ATRA and RIF in the treatment of pediatric APL. A total of 200 pediatric patients diagnosed with APL were enrolled from ten hospitals in China. The study revealed that arsenic plasma levels stabilized when RIF was administered at a dosage of 60 mg/kg per day, and maintaining white blood cell counts at or below 30 × 10⁹/L during induction therapy significantly reduced the risk of differentiation syndrome, thereby proving the protocol’s efficacy and safety.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Arsenic concentration</h3>
<p id="Par6">At the commencement of the CCCG-APL-2017 study, we aimed to establish real-world arsenic concentration levels by testing six pediatric patients (Supplementary Text <a href="#MOESM1" class="usa-link">1</a>). Due to the inconvenience associated with blood collection for oral RIF therapy, which is primarily administered at home, only six patients were included in the testing. Before medication, venous blood samples are taken to measure arsenic concentration. Subsequent measurements are taken at 7, 14, 21, and 28 days after commencing medication, as well as at 1, 3, 7, and 14 days after discontinuation. Our findings indicate that arsenic concentration increases with prolonged oral administration exceeding 60 mg/kg/day; however, it stabilizes after seven days. Furthermore, arsenic concentration returns close to pre-medication levels after a withdrawal period of fourteen days. This suggests that the toxic component of RIF-arsenic is metabolized naturally post-withdrawal and poses no further risk (Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>). The specific concentrations of arsenic can be found in Supplementary Table <a href="#MOESM1" class="usa-link">1</a>. The mean arsenic concentrations measured at 7, 14, 21, and 28 days following the administration of RIF were 55.4 ng/ml, 63.8 ng/ml, 72.7 ng/ml, and 74 ng/ml, respectively. The proportions of samples exhibiting arsenic concentrations that reached or exceeded 45.7 ng/ml (0.61 μmol/L) at each time point were recorded as follows: 66.7%, 83.3%, 83.3%, and 80%.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Patient characteristics</h3>
<p id="Par7">There are a total of 200 children from 10 hospitals were enrolled, with 82 in the high-risk (HR) group (47 males and 35 females) and 118 in the low-risk (LR) group (69 males and 49 females). All Parents agreed to enroll their children in the CCCG-APL-2017 protocol and signed the informed consent form, one child in the LR group was withdrawn due to stopped taking the drug 3 months earlier. Ultimately, a total of 199 patients completed the treatment and follow-up (Fig. <a href="#Fig1" class="usa-link">1</a>). The <em>PML/RARA</em> fusion gene status and chromosomal karyotype data are detailed in Supplementary Table <a href="#MOESM1" class="usa-link">2</a>. The baseline characteristics of these patients are presented in Table <a href="#Tab1" class="usa-link">1</a>. No notable differences were observed between the two groups concerning gender, age, initial clinical symptoms, or family history. Nevertheless, a significant disparity was found in the newly diagnosed level of WBC and proportion of naive cells in peripheral blood between the groups (Table <a href="#Tab1" class="usa-link">1</a>). Aside from this variation, baseline information was consistent between both groups.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/12370879/54a098206e6e/41392_2025_2353_Fig1_HTML.jpg" loading="lazy" id="d33e548" height="567" width="633" alt="Fig. 1"></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart for inclusion and treatment outcomes of APL patients. There are 200 APL patients from 10 hospitals enrolled, with 82 in the high-risk (HR) group and 118 in the low-risk (LR) group. One child in the LR group was withdrawn due to stopping taking the drug 3 months earlier. Ultimately, a total of 199 patients completed the treatment and follow-up. Two children in the HR group died, and two children in the LR group relapsed</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Basic information on enrolled patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Characteristics</th>
<th colspan="1" rowspan="1">LR</th>
<th colspan="1" rowspan="1">HR</th>
<th colspan="1" rowspan="1">
<em>p</em> value</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1"><strong><em>n</em></strong></td>
<td colspan="1" rowspan="1">117</td>
<td colspan="1" rowspan="1">82</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Gender, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.91</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Female</td>
<td colspan="1" rowspan="1">49 (41.9%)</td>
<td colspan="1" rowspan="1">35 (42.7%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Male</td>
<td colspan="1" rowspan="1">68 (58.1%)</td>
<td colspan="1" rowspan="1">47 (57.3%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Age (year), median (IQR)</strong></td>
<td colspan="1" rowspan="1">9 (7, 11)</td>
<td colspan="1" rowspan="1">10 (6.25, 12)</td>
<td colspan="1" rowspan="1">0.38</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<strong>WBC (×10</strong><sup><strong>9</strong></sup><strong>L), median (IQR)</strong>
</td>
<td colspan="1" rowspan="1">2.8 (1.83, 4.54)</td>
<td colspan="1" rowspan="1">23.17 (13.57, 54.29)</td>
<td colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<strong>HB (g/L), mean</strong> <strong>±</strong> <strong>SD</strong>
</td>
<td colspan="1" rowspan="1">81.97 ± 20.86</td>
<td colspan="1" rowspan="1">76.51 ± 22.99</td>
<td colspan="1" rowspan="1">0.08</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<strong>PLT (×10</strong><sup><strong>9</strong></sup><strong>L), median (IQR)</strong>
</td>
<td colspan="1" rowspan="1">33 (18, 58)</td>
<td colspan="1" rowspan="1">37 (16, 58.5)</td>
<td colspan="1" rowspan="1">0.94</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Proportion of naive cells in peripheral blood (%), median (IQR)</strong></td>
<td colspan="1" rowspan="1">15 (3, 42)</td>
<td colspan="1" rowspan="1">69.5 (40, 84)</td>
<td colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Fever, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.09</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">77 (65.8%)</td>
<td colspan="1" rowspan="1">63 (76.8%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">40 (34.2%)</td>
<td colspan="1" rowspan="1">19 (23.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Hemorrhage, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.13</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">37 (31.6%)</td>
<td colspan="1" rowspan="1">18 (22.0%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">80 (68.4%)</td>
<td colspan="1" rowspan="1">64 (78.0%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Arthralgia, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.60</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">106 (90.6%)</td>
<td colspan="1" rowspan="1">76 (92.7%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">11 (9.4%)</td>
<td colspan="1" rowspan="1">6 (7.3%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Central nervous system leukemia, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.47</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">1 (0.9%)</td>
<td colspan="1" rowspan="1">1 (1.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">116 (99.1%)</td>
<td colspan="1" rowspan="1">80 (97.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> UN</td>
<td colspan="1" rowspan="1">0 (0.0%)</td>
<td colspan="1" rowspan="1">1 (1.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Family history of tumors or Blood disorders, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.99</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">113 (96.6%)</td>
<td colspan="1" rowspan="1">80 (97.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">4 (3.4%)</td>
<td colspan="1" rowspan="1">2 (2.4%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Karyotype, n (%)</strong></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">0.70</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> no</td>
<td colspan="1" rowspan="1">5 (4.3%)</td>
<td colspan="1" rowspan="1">2 (2.4%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> yes</td>
<td colspan="1" rowspan="1">112 (95.7%)</td>
<td colspan="1" rowspan="1">80 (97.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p10"><p><em>HR</em> high-risk, <em>LR</em> low-risk, <em>WBC</em> white blood cell, <em>HB</em> hemoglobin, <em>PLT</em> platelet, <em>IQR</em> interquartile range (Q1, Q3), <em>SD</em> standard deviation, <em>UN</em> uncertainty</p></div></div></section></section><section id="Sec5"><h3 class="pmc_sec_title">Efficacy</h3>
<p id="Par8">The 6-year OS rate for total APL patients (Fig. <a href="#Fig2" class="usa-link">2a</a>) was 99.5%, while the HR group had a rate of 97.6% (Fig. <a href="#Fig2" class="usa-link">2b</a>). There were 2 dead cases, one of which died at first diagnosis due to cerebral hemorrhage during induction therapy. Another patient died due to septicemia during the first phase of consolidation therapy. The 6-year OS for the LR group was 100%, with no statistical difference observed between the two groups (Fig. <a href="#Fig2" class="usa-link">2b</a>). DS did not have an impact on OS in either LR or HR patients (Fig. <a href="#Fig2" class="usa-link">2c</a>). The 6-year total EFS was 98% for APL patients (Fig. <a href="#Fig2" class="usa-link">2d</a>), with a rate of EFS at 97.6% for HR patients and two associated deaths (Fig. <a href="#Fig2" class="usa-link">2e</a>). The LR group achieved an EFS of 98.3%, with two cases of relapse, showing no significant difference compared to the HR group’s performance (Fig. <a href="#Fig2" class="usa-link">2e</a>). One relapsed patient had a <em>PML/RARA</em> fusion gene level of 46.06% at diagnosis, which dropped to 0 after induction therapy. However, molecular recurrence occurred 2 years after chemotherapy was discontinued. Another patient had a positive <em>PML/RARA</em> fusion gene at diagnosis, with no quantification data. This patient had no detectable minimal residual disease (MRD) after induction therapy and consolidation 1, and MRD was negative with a quantification of 0 after consolidation 2. However, bone marrow relapsed 10 months after chemotherapy was stopped. Both patients tested negatively for FLT3-ITD (FMS-like tyrosine kinase 3—internal tandem duplication) mutation, and unfortunately, neither underwent next-generation sequencing. Patients experiencing relapses were treated with the HR group program of CCCG-APL-2017 and achieved prolonged survival. DS did not affect EFS (Fig. <a href="#Fig2" class="usa-link">2f</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370879_41392_2025_2353_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/12370879/e35febd9fe1c/41392_2025_2353_Fig2_HTML.jpg" loading="lazy" id="d33e927" height="517" width="725" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Survival prognosis analysis of risk and DS. <strong>a</strong> We conducted a prognosis analysis of OS for all patients. <strong>b</strong>, <strong>c</strong> OS prognosis analyses were performed for patients in different groups of risk (HR/LR) or DS (yes/no). <strong>d</strong>–<strong>f</strong> Prognosis analyses for EFS were conducted as well. The Kaplan-Meier survival curves with <em>p</em> value were provided. The number of patients at risk at each time is displayed below the respective survival curves. HR high-risk, LR low-risk</p></figcaption></figure><p id="Par9">Additionally, we analyzed different genders as well as whether induced differentiation syndrome occurred in different genders regarding its impact on OS and EFS. Our findings indicated that gender-specific occurrence of induced differentiation syndrome has no impact on OS and EFS outcomes (Supplementary Fig. <a href="#MOESM1" class="usa-link">2</a>).</p></section><section id="Sec6"><h3 class="pmc_sec_title">PML/RARA gene</h3>
<p id="Par10">Following induction therapy, 109 patients in the LR group and 72 patients in the HR group underwent testing for the <em>PML/RARA</em> fusion gene. The positive results were found in 31 patients, comprising 15.6% (17/109) in the LR group and 19.4% (14/72) in the HR group. After the first consolidation therapy, all patients in the LR group achieved <em>PML/RARA</em> fusion gene negativity, while one patient in the HR group failed to convert the gene. This patient subsequently achieved gene negativity after undergoing a second consolidation treatment (Fig. <a href="#Fig3" class="usa-link">3</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/12370879/a0fea3ca8f50/41392_2025_2353_Fig3_HTML.jpg" loading="lazy" id="d33e959" height="330" width="633" alt="Fig. 3"></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Positive rate of <em>PML/RARA</em> fusion gene during therapy. We analyzed the positive rate of <em>PML/RARA</em> fusion gene in patients at different stages before and after treatment and showed it through stereogram. HR high-risk, LR low-risk, PML/RARA promyelocytic leukemia/retinoic acid receptor alpha</p></figcaption></figure></section><section id="Sec7"><h3 class="pmc_sec_title">Differentiation syndrome</h3>
<p id="Par11">We analyzed the incidence, clinical manifestations, and risk factors of differentiation syndrome (DS) in induction therapy. During induction therapy, the overall incidence of DS was 38.7% (77/199). Specifically, the incidence of DS was 45.1% (37/82) among HR cases and 34.2% (40/117) among LR cases. All cases of DS were indeterminate,<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup> and no statistically significant difference was observed in the incidence between the two groups (Supplementary Table <a href="#MOESM1" class="usa-link">3</a>). No deaths related to DS were reported. Upon analyzing the risk factors influencing DS, it was found that the factors of WBC and PLT (platelet) were associated with DS occurrence (Supplementary Table <a href="#MOESM1" class="usa-link">4</a>).</p>
<p id="Par12">In addition, the nomogram tool enables clinicians to evaluate individual patient risk for specific diseases, thereby facilitating informed clinical decision-making and patient management.<sup><a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup> Thus, we also incorporated key clinical variables—namely WBC_base, HB_base, PLT_base, duration of chemotherapy, and infection status—into the development of a nomogram designed to predict the risk of differentiation syndrome (Fig. <a href="#Fig4" class="usa-link">4</a>). For instance, each variable of one patient is assigned a specific score based on its value, and these scores are aggregated to yield a total score of 309.5. This total score is then translated into a risk probability of approximately 50%, as depicted at the bottom of the nomogram (Fig. <a href="#Fig4" class="usa-link">4a</a>). Furthermore, we generated a calibration curve to assess the concordance between the nomogram’s predicted probabilities of differentiation syndrome and the actual observed probabilities. As illustrated in Fig. <a href="#Fig4" class="usa-link">4b</a>, the predicted probabilities closely match the observed probabilities, demonstrating good calibration and reliability of the model, which enhances the nomogram’s clinical applicability.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370879_41392_2025_2353_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/12370879/3f78d3270332/41392_2025_2353_Fig4_HTML.jpg" loading="lazy" id="d33e1005" height="412" width="790" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Nomogram and calibration curve of differentiation syndrome. <strong>a</strong> The nomogram integrates key clinical variables to estimate the probability of differentiation syndrome. Each variable is assigned a point value on the upper scale (e.g., 15 for WBC_base and 25 for HB_base). The total score, derived from summing up the points for all variables (e.g., a cumulative score of 309.5), is then referenced on the lower axis to determine the corresponding predicted probability (e.g., approximately 50% risk in this instance). <strong>b</strong> The calibration curve evaluates the agreement between predicted and observed probabilities. The apparent line (blue dashed) represents uncorrected predictions, the bias corrected line (yellow dashed) shows adjusted predictions, and the ideal line (gray dashed) indicates perfect calibration. WBC white blood cell, HB hemoglobin, PLT platelet</p></figcaption></figure></section><section id="Sec8"><h3 class="pmc_sec_title">Treatment toxicities</h3>
<p id="Par13">We assessed the toxic side effects according to CTCAE (common terminology criteria for adverse events) 4.0 during induction treatment phase (Supplementary Table <a href="#MOESM1" class="usa-link">5</a>). 89.9% of patients (179/199) experienced grade 3–4 anemia, while 90.95% experienced grade 3–4 neutropenia (181/199), and 86.9% experienced grade 3–4 thrombocytopenia (173/199). Additionally, the incidence of disseminated DIC is 37.2% (74/199) with grade 3–5 DIC occurring in 15.1% (30/199) of patients, with one patient in the HR group succumbing to grade 5 DIC with intracranial hemorrhage. The overall incidence of bleeding was 36.2% (72/199), with severe bleeding (grade 3–5) occurring in 5% (10/199). The bleeding rates were significantly higher in the HR group at 51.2% (42/82), compared to 25.6% (30/117) in the LR group. Notably, abnormal coagulation remains a significant factor contributing to early death. The incidence of thrombus was 2% (4/199). In the LR group, the incidence of thrombus was 1.7% (2/117), with one case of grade 1 accompanied by grade 4 hemorrhage and DIC, and one case of grade 2 without hemorrhage and DIC. In the HR group, the incidence of thrombus was 2.4% (2/82), all of which were grade 2 and accompanied by grade 2 hemorrhage, with one case of grade 1 DIC and one case of grade 3 DIC. Regarding cardiotoxicity, only 6% (12/199) of patients experienced prolonged corrected QT intervals at grades 1–2. The cardiotoxicity incidence was 7.3% (6/82) in the HR group, and 5.1% (6/117) in the LR group, respectively. No notable distinction was observed between the two groups. All these 12 patients had grade 1–2 cardiac toxicity and could recover with supportive treatment. Additionally, 7% (14/199) had elevated serum ALT/AST (alanine transaminase / aspartate aminotransferase) levels at a grade 3 level, while hyperbilirubinemia, was found in grades 1–2 for about 6.5% (13/199) of patients.</p>
<p id="Par14">Due to the distinct treatment protocols for the LR and HR groups during the consolidation and maintenance phases, we performed a separate analysis of the toxic reactions in each group. In the LR group, the incidence of hematological toxicity and hepatotoxicity was significantly elevated during the initial stage of consolidation treatment compared to other treatment stages (Supplementary Fig. <a href="#MOESM1" class="usa-link">3</a> left panel and Supplementary Table <a href="#MOESM1" class="usa-link">6</a><em>, p</em> &lt; 0.05). Additionally, in the second stage of consolidation treatment, QTc (corrected QT interval) prolongation was observed in only one patient (grade 1) of LR group (Supplementary Table <a href="#MOESM1" class="usa-link">6</a>). In contrast, the HR group exhibited a significant increase in the incidences of hematological toxicity, cardiotoxicity, hepatotoxicity, nausea, vomiting, and infectious fever during the consolidation treatment stage (Supplementary Fig. <a href="#MOESM1" class="usa-link">3</a> right panel and Supplementary Table <a href="#MOESM1" class="usa-link">7</a>, <em>p</em> &lt; 0.05), which may be attributed to the infusion of Idarubicin. Notably, ALT and AST levels remained persistently elevated, with this abnormality continuing until the second stage of maintenance treatment (Supplementary Fig. <a href="#MOESM1" class="usa-link">3</a> right panel). During the first and second stages of consolidation treatment, five patients (grade 1) of HR group displayed prolonged QTc (Supplementary Table <a href="#MOESM1" class="usa-link">7</a>). More critically, there was one fatality due to sepsis during the first stage of consolidation treatment. A comprehensive analysis indicates that the overall toxicity level of patients in the HR group was higher than that in the LR group throughout the entire consolidation and maintenance treatment period.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Infection</h3>
<p id="Par15">In our study, infections were classified into two distinct categories. The first category encompassed fever associated with a clear focus on infection, such as oral, pulmonary, or bloodstream infections, irrespective of the presence of DS. This type of fever was substantiated by clinical or laboratory evidence indicating an infection. The second category included fever without a discernible focus of infection and with DS excluded; this typically occurred during granulocytopenia and is referred to as isolated fever (i.e., “no obvious infection” in Supplementary Fig. <a href="#MOESM1" class="usa-link">4</a>). In clinical practice, we generally consider that fever induced solely by ATRA and arsenic agents during the early treatment phase—regardless of accompanying muscle pain and in the absence of an evident infectious focus—may signify induction syndrome and can be effectively managed with corticosteroids. In contrast, fever accompanied by a clear infectious source or positive indicators related to infection (e.g., blood culture positivity) is categorized as infectious. The overall infection rate was 76% (151/199) during induction therapy, and there was no notable distinction between the LR and HR categories in terms of infection prevalence (Supplementary Table <a href="#MOESM1" class="usa-link">8</a>).</p>
<p id="Par16">Among the sites of infection, pulmonary infections were the most common, with HR patients being more susceptible to developing pulmonary infections (Supplementary Fig. <a href="#MOESM1" class="usa-link">4</a>). Pathogens were detected in 23 patients, including four cases of mycoplasma pneumoniae, of which two had other infections, one had aureus septicemia, and one had herpes simplex virus. Three cases of pulmonary fungal infections, and six cases of pulmonary bacterial infections, which included Streptococcus, Haemophilus influenzae, MRSA (Methicillin-resistant Staphylococcus aureus) + perianal swab enzyme-producing Escherichia coli from a throat swab, Stenotrophomonas maltophilia, Streptococcus pneumoniae. Additionally, there were four cases of viral infections: herpes simplex virus (2 cases), varicella-zoster virus (1 case), and unknown virus (1 case). Five cases of sepsis caused by Micrococcus luteus, Streptococcus agalactiae subsp. agalactiae, Staphylococcus aureus, Staphylococcus hominis subsp. hominis, and MRSA. Furthermore, there was one case involving intestinal trichomonas.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Gene mutation</h3>
<p id="Par17">Out of 199 patients, mutation data for specific genes was obtained from 138 individuals. Among these, 34 patients exhibited no gene mutations, while mutations such as FLT3-ITD, FLT3-TKD (FMS-like tyrosine kinase 3—tyrosine kinase domain), NRAS (Neuroblastoma RAS viral oncogene homolog), KRAS (Kirsten rat sarcoma viral oncogene homolog), and WT1 (Wilms tumor 1) were detected in 104 patients. Supplementary Fig. <a href="#MOESM1" class="usa-link">5</a> presents a heat map of these mutant genes, showing that the mutation frequencies of FLT3-ITD and FLT3-TKD were higher in the HR group than in the LR group. Correlation analysis (Supplementary Table <a href="#MOESM1" class="usa-link">9</a>) revealed that the HR group had a higher FLT3-ITD mutation rate (36.5% vs. 13.3%, <em>p</em> = 0.001) and a higher FLT3-TKD mutation rate (30.2% vs. 10.7%, <em>p</em> = 0.004) compared to the LR group. Additionally, no significant correlation was found between these gene mutations and the occurrence of DS (Supplementary Table <a href="#MOESM1" class="usa-link">10</a>). Notably, none of the patients with FLT3-ITD or FLT3-TKD mutations experienced a relapse; however, it is regrettable that the two patients who did relapse did not undergo next-generation sequencing.</p>
<p id="Par18">Subsequently, we investigated whether single-gene mutations (e.g., FLT3-ITD, FLT3-TKD, NRAS) or dual-gene mutations (e.g., FLT3-ITD/TKD, FLT3-ITD/NRAS) influence the increase in WBC (WBC_highest / base) and the decrease in PLT (PLT_lowest / base) during induction therapy. The results, shown in Supplementary Fig. <a href="#MOESM1" class="usa-link">6</a>-<a href="#MOESM1" class="usa-link">7</a>, indicated no significant effects.</p>
<p id="Par19">Finally, we conducted a Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis using these identified mutant genes (Supplementary Fig. <a href="#MOESM1" class="usa-link">8</a>). Our analysis revealed that these gene mutations are predominantly associated with blood cell differentiation. Furthermore, the analysis indicated enrichment in categories such as DNA-binding transcription factor binding, transcription coregulator activity, and ATPase complex. A series of mutant genes linked to gene transcription, particularly those associated with the transcription regulator complex, suggests that the regulatory networks of genes involved in blood cell differentiation may play a significant role in the underlying mechanisms of APL in children.</p></section></section><section id="Sec11"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par20">Previous reports indicate that As<sub>2</sub>O<sub>3</sub> primarily induces apoptosis at higher concentrations (0.5–2 μmol/L) and partial differentiation at lower concentrations (0.1 to 0.5 μmol/L) in APL cells.<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup> Comparing RIF at 135 mg/kg/day to ATO at 0.16 mg/kg/day, both have similar plasma arsenic levels, with troughs around 0.5–1 µmol/L.<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> However, at 60 mg/kg/day of RIF versus 0.16 mg/kg/day of ATO, the trough levels were 11.5 µg/L for RIF and 21.7 µg/L for ATO.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> Our findings show that a 60 mg/kg/d oral RIF dosage results in an average arsenic concentration of 0.74 μmol/L by day 7 in children. Chen et al. reported an increase in myelocyte-like cells in bone marrow and peripheral blood examinations after 2 to 3 weeks of continuous As<sub>2</sub>O<sub>3</sub> treatment in vivo, coinciding with a decrease in leukemic promyelocytes.<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup> To ensure efficacy, we opted for a 60 mg/kg/d oral maintenance dosage over 3–4 weeks. A higher dosage of the AS<sub>4</sub>S<sub>4</sub> may be harmful to both liver and kidney functions, particularly in children.<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup> After drug withdrawal, arsenic levels returned to pre-treatment levels within 14 days. Therefore, our treatment protocol is to include a rest period of 2–3 weeks between different courses of treatment. This protocol supports the scientific use and dosage of RIF. After a median follow-up of 3.9 years, treatment effects remained stable. RIF can be taken orally at home, offering a more convenient and cost-effective option than ATO, reducing financial strain on families and allowing children to return to normal activities sooner.</p>
<p id="Par21">In pediatric APL treatment, oral RIF combined with ATRA is as effective as intravenous ATO/ATRA.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>,<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>,<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup> Zheng et al. reported a 99% 2-year overall survival with oral therapy per the CCLG-APL 2016 Protocol.<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> Luo et al. found a 100% disease-free survival rate in both treatment groups after two years.<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> Huang et al. noted a 97.6% 5-year EFS rate for both ATO and oral therapy groups in the SCCLG-APL study.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> Our study, with 199 patients, showed a 100% 6-year OS rate in the LR group and 97.6% in the HR group, with EFS rates of 98.3% and 97.6%, respectively. Among 199 patients, EFS was slightly higher in those with DS than without, but not significantly (Fig. <a href="#Fig2" class="usa-link">2f</a>, <em>p</em> = 0.669). Of these patients, 130 received cytarabine, averaging 4 days of treatment (median 8 days, range 1–27) and a mean dose of 803 mg (median 700 mg, range 35–2940 mg). Cytarabine was administered to 81.8% of DS patients and 54.9% of non-DS patients (<em>p</em> &lt; 0.001) (Supplementary Table <a href="#MOESM1" class="usa-link">11</a>). In addition, we analyzed the link between cytarabine treatment and OS/EFS. Supplementary Fig. <a href="#MOESM1" class="usa-link">9</a> shows that patients treated with cytarabine had a more favorable trend in OS and EFS, though not statistically significant. This aligns with EFS outcomes in DS-related cases, suggesting cytarabine may improve EFS in DS patients. In induction therapy, our neutropenia rate (90.95%, grade 3 + 4) surpassed Zheng et al.‘s 80%,<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> likely due to cytarabine and hydroxyurea. Infections during this phase are diverse and impactful, necessitating multiple blood cultures for pathogen identification and broad-spectrum antimicrobials if the cause is unclear. Pulmonary infections are most common, warranting early CT scans for recurrent fever. During the consolidation and maintenance phase, the toxicity of oral ARTA and RIF was less than ATO combined with ATRA and also lower than oral 135 mg/kg/d of RIF, especially the incidence of QTc prolongation.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>,<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a></sup> This might be linked to RIF’s traditional Chinese medicine properties, though further research on its compound effects is needed.</p>
<p id="Par22">This study is designed as a single-arm investigation. Given the rarity of pediatric APL and the well-documented efficacy of combining arsenic with ATRA in treating pediatric APL patients, this approach is justified. Due to the lack of consensus regarding the combination of oral RIF with ATRA, the single-arm design was implemented to standardize the treatment of APL using RIF and ATRA, thereby facilitating increased patient enrollment. Consequently, our investigation, guided by experts from our clinical epidemiology and evidence-based medicine center, was structured as a single-arm study involving children diagnosed with APL. Furthermore, we acknowledge that the absence of comprehensive second-generation sequencing analysis and a systematic evaluation of concurrent mutations may limit the generalizability of our conclusions. Variations in clinical workflows and resource availability across participating institutions have resulted in inconsistent implementation of genomic sequencing protocols, leading to some patients not receiving sequencing. To address this limitation, we plan to conduct additional comprehensive genomic sequencing analysis, focusing on specific gene mutation sites and the mutation status of other related genes. This approach will allow for a more systematic assessment of mutational patterns and their prognostic implications, thereby enhancing the validity of our findings.</p>
<p id="Par23">Different studies use various criteria for risk classification in APL patients. Huang et al. categorized patients into LR, intermediate-risk, and HR based on WBC and platelet levels.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> Zheng grouped patients into standard risk and HR based on WBC count and FLT3-ITD mutations.<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> Since FLT3-ITD does not affect APL aggressiveness in adult,<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup> our study classified patients into LR and HR groups based solely on WBC count for simplicity and feasibility. We found FLT3-ITD and FLT3-TKD mutations are more common in the HR group (Supplementary Table <a href="#MOESM1" class="usa-link">10</a>). No patients with these mutations experienced relapse or death, suggesting they are not linked to disease recurrence but may correlate with higher WBC counts. Previous studies reported ATRA and ATO-associated DS incidence between 2.5% and 37%, with onset typically between 7 and 12 days.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>–<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup> Severe DS appears sooner, around 6 days, while moderate cases develop around 15 days.<sup><a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup> In our study, DS incidence was 38.7%. We treated indeterminate-grade DS with glucocorticoids, hydroxyurea, and cytarabine to maintain white blood cells at 50 × 10<sup>9</sup>/L, effectively reducing pain and mortality. Analysis of risk factors for DS revealed that the risk increases when the WBC count rises above 30 × 10<sup>9</sup>/L. To mitigate the risk of DS in later stages, cytarabine should be administered when the WBC count reaches 30 × 10<sup>9</sup>/L, rather than waiting until it reaches 50 × 10<sup>9</sup>/L.</p>
<p id="Par24">In conclusion, our findings demonstrate that the CCCG-APL-2017 protocol based on ATRA and RIF for treating pediatric APL is effective and has a low incidence of side effects. The recommended dosage of RIF is 60 mg/kg/d, with a suggested duration of 3–4 weeks. To mitigate the risk of differentiation syndrome, it is advisable to maintain WBC counts at or below 30 × 10<sup>9</sup>/L.</p></section><section id="Sec12"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec13"><h3 class="pmc_sec_title">Study design and patients</h3>
<p id="Par25">The CCCG-APL-2017 study is a multi-center, single-arm clinical trial. Its primary objective is to evaluate the EFS and OS associated with the CCCG-APL-2017 protocol, which combines RIF and ATRA for the treatment of pediatric APL. Secondary objectives include assessing the time to achieve fusion gene negativity and its corresponding rate, reducing both the incidence and severity of DS, as well as evaluating the safety profile of the RIF and ATRA combination therapy, particularly concerning the incidence and severity of adverse events. The study involved 200 children diagnosed with APL, recruited from October 2017 to June 2022. A total of 200 children from 10 hospitals were enrolled, including 55 in the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, 38 in Shanghai Children’s Medical Center, 34 in West China Second University Hospital, 22 in Guangzhou Women and Children’s Medical Center, 18 in Children’s Hospital of Chongqing Medical University, 15 in Qilu Hospital of Shandong University, 8 in Quanzhou First Hospital Affiliated to Fujian Medical University, 4 in the First Hospital of Jilin University. 2 in the affiliated hospital of Qingdao University and 4 in Zhangzhou Municipal Hospital of Fujian Province. Confirmation of APL diagnosis was based on bone marrow cell morphology, as well as the detection of the <em>PML/RARA</em> fusion gene or t (15;17) chromosomal translocation. The age range of participants in this research varied from 29 days to 18 years. Registration for this study was completed at the Chinese Clinical Trial Registry under the code ChiCTR-OIC-16010014. This study was approved by the Ethics Committee of Hematology Hospital, Chinese Academy of Medical Sciences (IIT2016008-EC-2). The informed consent was provided by patients’ families and/or patients themselves following the Declaration of Helsinki.</p></section><section id="Sec14"><h3 class="pmc_sec_title">Treatment protocol</h3>
<p id="Par26">The treatment protocols are shown in Fig. <a href="#Fig5" class="usa-link">5</a>. Further instructions can be found in Supplementary Text <a href="#MOESM1" class="usa-link">2</a>. The risk group has been defined as follows: LR group, which includes individuals with peripheral blood WBC &lt; 10 × 10<sup>9</sup>/L before ATRA or/and ATO treatment and good treatment response (<em>PML/RARA</em> negative after two consolidation treatments); HR group, which encompasses those with peripheral blood WBC ≥ 10 × 10<sup>9</sup>/L before ATRA or/and ATO treatment, or those with unsatisfactory treatment response (such as patients in the original LR group who do not achieve complete response after 56 days of induction therapy, or those who do not have negative <em>PML/RARA</em> after two courses of consolidation therapy, or they have positive <em>PML/RARA</em> for two consecutive times after it turns negative), or those experiencing a molecular genetic relapse. To conserve medical resources and minimize the toxic and adverse reactions of chemotherapeutic drugs, intravenous arsenic is discontinued following a response, and instead, RIF at a dosage of 60 mg/kg/d is used. For LR APL cases post-response, cytotoxic chemotherapeutic agents should be avoided while utilizing RIF (60 mg/kg/d) and ATRA (25–30 mg/m<sup>2</sup>). It is advised to early administer dexamethasone prophylactically to lessen the frequency and seriousness of differentiation syndrome. Patients with WBC more than 5 × 10<sup>9</sup>/L are treated with hydroxycarbamide 20–50 mg/kg/d for more than three days, and it is recommended to continue until WBC decreases to ≤10 × 10<sup>9</sup>/L. Patients with WBC ≥ 50 × 10<sup>9</sup>/L during ATRA + ATO therapy are given cytarabine (Ara-c) 50 mg/m<sup>2</sup> intravenously for 12 h until WBC decreases to ≤ 10 × 10<sup>9</sup>/L.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370879_41392_2025_2353_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/12370879/db2e37b6c0e8/41392_2025_2353_Fig5_HTML.jpg" loading="lazy" id="d33e1284" height="390" width="790" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Treatment protocols of CCCG-APL-2017. The APL patients were divided into low-risk and high-risk groups according to whether the white blood cells were less than 10 × 10<sup>9</sup>/L before ATRA or/and ATO treatment, the patients APL patients underwent induction therapy, consolidation therapy, and maintenance therapy in three stages. APL acute promyelocytic leukemia, ATO arsenic trioxide, ATRA all-trans retinoic acid, IDA Idarubicin, IT Lumbar puncture combined with triple sheath injection, BM bone marrow aspiration, RIF Realgar-Indigo Naturalis formula, 6MP 6-Mercaptopurine, MTX methotrexate, QN quaque nocte, QW quaque week</p></figcaption></figure></section><section id="Sec15"><h3 class="pmc_sec_title">Sample size setting</h3>
<p id="Par27">Sample size setting was performed using the “One-Sample Logrank Tests Assuming a Weibull Model (Wu)” Procedure in PASS 2021 software. The calculation was based on 3-year EFS rates, with a historical control rate of 90% and an anticipated trial rate of 95%, α = 0.05, power = 80%, a 4-year recruitment period, and 3-year follow-up. The calculated sample size was 151 patients, adjusted to 167 considering a 10% dropout rate. Due to the COVID-19 (coronavirus disease-2019) pandemic and low incidence of pediatric APL, enrollment was delayed by 8 months. To account for potential increased dropouts during the pandemic, the dropout rate was raised to 30%, resulting in a recalculated sample size of 196, approximately 200 patients. Fortunately, no patients were lost to follow-up, likely due to the oral administration protocol allowing remote guidance during the pandemic.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Response criteria</h3>
<p id="Par28">Complete response: &lt;5% of bone marrow promyelocytes; absence of blasts with Auer corpuscles, the persistence of extramedullary leukemia, and no extramedullary leukemia. Absolute neutrophil count ≥1.0 × 10<sup>9</sup>/L, platelet count ≥100 × 10<sup>9</sup>/L. Partial response: 5%-25% of bone marrow promyelocytes. Molecular genetic response: Negative result for <em>PML/RARA</em> fusion gene in bone marrow as determined by nested reverse transcription-polymerase chain reaction (RT-PCR) analysis. No response: &gt;25% bone marrow promyelocytes. Drug resistance: failure to achieve complete response after 56 days of induction therapy. Relapse: &gt; 20% bone marrow promyelocytes after achieving a previous response. Molecular genetic relapse: RT-PCR initially shows a negative result for the <em>PML/RARA</em> fusion gene, followed by two subsequent positive results with an interval of 2–3 weeks.</p></section><section id="Sec17"><h3 class="pmc_sec_title">Gene mutation analysis</h3>
<p id="Par29">We systematically collected (Supplementary Table <a href="#MOESM1" class="usa-link">12</a>) and evaluated accessible genomic mutation information. By integrating patient risk strata with gene mutation profiles, we conducted a comprehensive analysis. This was followed by risk categorization and result visualization, executed using the pheatmap R package. Gene identifiers were standardized utilizing the org.Hs.eg.db R package. We performed functional enrichment analyses on GO categories, encompassing biological processes (BP), cellular components (CC), and molecular functions (MF), in conjunction with KEGG pathways. The clusterProfiler R package was employed for these analyses, with results presented through ggplot2. Furthermore, we integrated mutation data with survival outcomes and clinical metrics to investigate associations between single and dual gene mutation types.</p></section><section id="Sec18"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par30">If the data from measurements follows a normal distribution, they should be represented as mean ± standard deviation (SD). When comparing two groups of samples, a <em>t</em> test is used. If the measurement data do not follow a normal distribution, a Mann–Whitney U test was utilized to evaluate the differences between groups. A chi-square test was performed using the stats [4.2.1] R package. For the Nomogram and standard curve analysis, we utilized the rms [6.4-0] R package to fit the model and calculate the risk scores of each variable. Additionally, we employed Resource Selection [0.3-5] to measure the calibration degree of the model. The glm function was used to construct a binary logistic model, and the rms package Calibration was utilized for analysis and visualization purposes.</p>
<p id="Par31">We conducted survival analyses for OS and EFS. OS was defined as the time from the initiation of treatment in the single-arm trial to death from any cause. EFS was measured from the start of treatment to the first occurrence of any event, including disease progression, local or distant recurrence, or death from any cause. For the analysis, we used the Surv function to create survival objects and the survfit function to perform Kaplan-Meier analysis. Kaplan-Meier survival curves were visualized using the survminer and ggplot2 packages, and the Log-rank test was applied to assess statistical significance. A <em>p-</em>value threshold of 0.05 was set to determine statistical significance. All analyses were conducted using IBM SPSS Statistics version 20.0 and R software (version 4.2.1).</p></section></section><section id="Sec19"><h2 class="pmc_sec_title">Supplementary information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12370879/bin/41392_2025_2353_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">supplementary material</a><sup> (2.4MB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>This work was supported by National Key Research and Development Program of China (2021YFE0106900), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-041, 2021-I2M-1-001), and the National Natural Science Foundation of China (82270144).</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>S.S., X.Z., X.J., L.Z., and Z.W. were responsible for designing the protocol and writing the protocol. L.C., J.G., X.L., and Y.H. were responsible for providing cases, writing the paper, extracting and analyzing data, interpreting results, and updating reference lists. S.Z., C.L., K.W., L.W., X.G., Q.L., P.W., Y.Z., M.Y., W.L., H.C., and M.Z. contributed to data extraction and provided cases on the study. All authors have read and approved the article.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data availability</h2>
<p>The available raw sequence data have been deposited in the Genome Sequence Archive (GSA) at the National Genomics Data Center, China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences (GSA-Human: HRA012149, HRA012104) that are publicly accessible at <a href="https://ngdc.cncb.ac.cn/gsa-human" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ngdc.cncb.ac.cn/gsa-human</a>. The datasets generated during this study are available upon request from the corresponding authors.</p></section><section id="FPar1"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par32">The authors declare no competing interests.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Publisher’s note</strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div class="fn p" id="fn2"><p>These authors contributed equally: Lixian Chang, Ju Gao, Xiaoying Lei, Yingyi He</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Xiuli Ju, Email: jxlqlyy@163.com.</p>
<p>Li Zhang, Email: zhangli1@ihcams.ac.cn.</p>
<p>Zhuo Wang, Email: wangzhuo111@sina.com.</p></section><section id="sec20"><h2 class="pmc_sec_title">Supplementary information</h2>
<p>The online version contains supplementary material available at 10.1038/s41392-025-02353-1.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Rérolle, D., Wu, H. C. &amp; de Thé, H. Acute promyelocytic leukemia, retinoic acid, and arsenic: A tale of dualities. <em>Cold Spring Harb. Perspect. Med</em><strong>14</strong>, a041582 (2024).
</cite> [<a href="https://doi.org/10.1101/cshperspect.a041582" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11368190/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38503502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?R%C3%A9rolle,%20D.,%20Wu,%20H.%20C.%20&amp;%20de%20Th%C3%A9,%20H.%20Acute%20promyelocytic%20leukemia,%20retinoic%20acid,%20and%20arsenic:%20A%20tale%20of%20dualities.%20Cold%20Spring%20Harb.%20Perspect.%20Med14,%20a041582%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Chen, J. &amp; Ding, Z. Natural products as potential drug treatments for acute promyelocytic leukemia. <em>Chin. Med.</em><strong>19</strong>, 57 (2024).
</cite> [<a href="https://doi.org/10.1186/s13020-024-00928-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10988969/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38566147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20J.%20&amp;%20Ding,%20Z.%20Natural%20products%20as%20potential%20drug%20treatments%20for%20acute%20promyelocytic%20leukemia.%20Chin.%20Med.19,%2057%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Cheng, Y. et al. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. <em>Eur. J. Haematol.</em><strong>91</strong>, 483–489 (2013).
</cite> [<a href="https://doi.org/10.1111/ejh.12194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24033687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cheng,%20Y.%20et%20al.%20Long-term%20prognosis%20of%20childhood%20acute%20promyelocytic%20leukaemia%20with%20arsenic%20trioxide%20administration%20in%20induction%20and%20consolidation%20chemotherapy%20phases:%20a%20single-centre%20experience.%20Eur.%20J.%20Haematol.91,%20483%E2%80%93489%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Chen, G. Q. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. <em>Blood</em><strong>88</strong>, 1052–1061 (1996).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/8704214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20G.%20Q.%20et%20al.%20In%20vitro%20studies%20on%20cellular%20and%20molecular%20mechanisms%20of%20arsenic%20trioxide%20(As2O3)%20in%20the%20treatment%20of%20acute%20promyelocytic%20leukemia:%20As2O3%20induces%20NB4%20cell%20apoptosis%20with%20downregulation%20of%20Bcl-2%20expression%20and%20modulation%20of%20PML-RAR%20alpha/PML%20proteins.%20Blood88,%201052%E2%80%931061%20(1996)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. <em>Blood</em><strong>72</strong>, 567–572 (1988).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/3165295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang,%20M.%20E.%20et%20al.%20Use%20of%20all-trans%20retinoic%20acid%20in%20the%20treatment%20of%20acute%20promyelocytic%20leukemia.%20Blood72,%20567%E2%80%93572%20(1988)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Kutny, M. A. et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children’s oncology group AAML1331 Trial. <em>JAMA Oncol.</em><strong>8</strong>, 79–87 (2022).
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2021.5206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8587220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34762093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kutny,%20M.%20A.%20et%20al.%20Assessment%20of%20arsenic%20trioxide%20and%20all-trans%20retinoic%20acid%20for%20the%20treatment%20of%20pediatric%20acute%20promyelocytic%20leukemia:%20A%20report%20from%20the%20children%E2%80%99s%20oncology%20group%20AAML1331%20Trial.%20JAMA%20Oncol.8,%2079%E2%80%9387%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Zhu, H. H., Hu, J., Lo-Coco, F. &amp; Jin, J. The simpler, the better: Oral arsenic for acute promyelocytic leukemia. <em>Blood</em><strong>134</strong>, 597–605 (2019).
</cite> [<a href="https://doi.org/10.1182/blood.2024027836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40208647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu,%20H.%20H.,%20Hu,%20J.,%20Lo-Coco,%20F.%20&amp;%20Jin,%20J.%20The%20simpler,%20the%20better:%20Oral%20arsenic%20for%20acute%20promyelocytic%20leukemia.%20Blood134,%20597%E2%80%93605%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Woods, A. C. &amp; Norsworthy, K. J. Differentiation syndrome in acute leukemia: APL and beyond. <em>Cancers (Basel)</em><strong>15</strong>, 4767 (2023).
</cite> [<a href="https://doi.org/10.3390/cancers15194767" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10571864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37835461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Woods,%20A.%20C.%20&amp;%20Norsworthy,%20K.%20J.%20Differentiation%20syndrome%20in%20acute%20leukemia:%20APL%20and%20beyond.%20Cancers%20(Basel)15,%204767%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Stahl, M. &amp; Tallman, M. S. Differentiation syndrome in acute promyelocytic leukaemia. <em>Br. J. Haematol.</em><strong>187</strong>, 157–162 (2019).
</cite> [<a href="https://doi.org/10.1111/bjh.16151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31410848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stahl,%20M.%20&amp;%20Tallman,%20M.%20S.%20Differentiation%20syndrome%20in%20acute%20promyelocytic%20leukaemia.%20Br.%20J.%20Haematol.187,%20157%E2%80%93162%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Wang, L. et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. <em>Proc. Natl. Acad. Sci. USA</em><strong>105</strong>, 4826–4831 (2008).
</cite> [<a href="https://doi.org/10.1073/pnas.0712365105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2290784/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18344322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20L.%20et%20al.%20Dissection%20of%20mechanisms%20of%20Chinese%20medicinal%20formula%20Realgar-Indigo%20naturalis%20as%20an%20effective%20treatment%20for%20promyelocytic%20leukemia.%20Proc.%20Natl.%20Acad.%20Sci.%20USA105,%204826%E2%80%934831%20(2008)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Huang, D.-P. et al. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. <em>Blood Cancer J.</em><strong>13</strong>, 178 (2023).
</cite> [<a href="https://doi.org/10.1038/s41408-023-00949-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10698191/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38052803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang,%20D.-P.%20et%20al.%20Long-term%20outcome%20of%20children%20with%20acute%20promyelocytic%20leukemia:%20a%20randomized%20study%20of%20oral%20versus%20intravenous%20arsenic%20by%20SCCLG-APL%20group.%20Blood%20Cancer%20J.13,%20178%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Zhu, H. H. et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. <em>J. Clin. Oncol.</em><strong>31</strong>, 4215–4221 (2013).
</cite> [<a href="https://doi.org/10.1200/JCO.2013.48.8312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24127444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu,%20H.%20H.%20et%20al.%20Oral%20tetra-arsenic%20tetra-sulfide%20formula%20versus%20intravenous%20arsenic%20trioxide%20as%20first-line%20treatment%20of%20acute%20promyelocytic%20leukemia:%20a%20multicenter%20randomized%20controlled%20trial.%20J.%20Clin.%20Oncol.31,%204215%E2%80%934221%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Luo, S. et al. Oral realgar-indigo naturalis formula treatment for acute promyelocytic leukemia in children: A randomized, control clinical trial. <em>Evid. Based Complement Altern. Med.</em><strong>2022</strong>, 8314176 (2022).</cite> [<a href="https://doi.org/10.1155/2022/8314176" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9276483/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35836830/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo,%20S.%20et%20al.%20Oral%20realgar-indigo%20naturalis%20formula%20treatment%20for%20acute%20promyelocytic%20leukemia%20in%20children:%20A%20randomized,%20control%20clinical%20trial.%20Evid.%20Based%20Complement%20Altern.%20Med.2022,%208314176%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Jiang, H. et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. <em>Leuk. Res</em><strong>39</strong>, 1319–1324 (2015).
</cite> [<a href="https://doi.org/10.1016/j.leukres.2015.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26403986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jiang,%20H.%20et%20al.%20Reduced%20medical%20costs%20and%20hospital%20days%20when%20using%20oral%20arsenic%20plus%20ATRA%20as%20the%20first-line%20treatment%20of%20acute%20promyelocytic%20leukemia.%20Leuk.%20Res39,%201319%E2%80%931324%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Huang, Q. et al. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms. <em>Chin. Herb. Med</em><strong>14</strong>, 154–165 (2022).
</cite> [<a href="https://doi.org/10.1016/j.chmed.2021.09.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9476755/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36120125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang,%20Q.%20et%20al.%20Safety%20and%20efficacy%20of%20Compound%20Huangdai%20Tablets%20combined%20with%20all-trans%20retinoic%20acid%20for%20treatment%20of%20acute%20promyelocytic%20leukemia:%20Clinical%20evidence%20and%20potential%20mechanisms.%20Chin.%20Herb.%20Med14,%20154%E2%80%93165%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Zheng, H. et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. <em>J. Clin. Oncol.</em><strong>39</strong>, 3161–3170 (2021).
</cite> [<a href="https://doi.org/10.1200/JCO.20.03096" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8478377/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34077242/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng,%20H.%20et%20al.%20Arsenic%20Combined%20With%20All-Trans%20Retinoic%20Acid%20for%20Pediatric%20Acute%20Promyelocytic%20Leukemia:%20Report%20From%20the%20CCLG-APL2016%20Protocol%20Study.%20J.%20Clin.%20Oncol.39,%203161%E2%80%933170%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Liao, L. H. et al. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia. <em>Cancer Chemother. Pharm.</em><strong>90</strong>, 45–52 (2022).</cite> [<a href="https://doi.org/10.1007/s00280-022-04449-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35760920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liao,%20L.%20H.%20et%20al.%20The%20comparison%20of%20plasma%20arsenic%20concentration%20and%20urinary%20arsenic%20excretion%20during%20treatment%20with%20Realgar-Indigo%20naturalis%20formula%20and%20arsenic%20trioxide%20in%20children%20with%20acute%20promyelocytic%20leukemia.%20Cancer%20Chemother.%20Pharm.90,%2045%E2%80%9352%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Zhang, L. et al. Population pharmacokinetics and safety of oral tetra-arsenic tetra-sulfide formula in pediatric acute promyelocytic leukemia. <em>Drug Des. Devel Ther.</em><strong>15</strong>, 1633–1640 (2021).
</cite> [<a href="https://doi.org/10.2147/DDDT.S305244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8071704/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33911851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang,%20L.%20et%20al.%20Population%20pharmacokinetics%20and%20safety%20of%20oral%20tetra-arsenic%20tetra-sulfide%20formula%20in%20pediatric%20acute%20promyelocytic%20leukemia.%20Drug%20Des.%20Devel%20Ther.15,%201633%E2%80%931640%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Chang, L. et al. Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients. <em>Open Med (Wars.)</em><strong>18</strong>, 20230847 (2023).
</cite> [<a href="https://doi.org/10.1515/med-2023-0847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10655686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38025539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chang,%20L.%20et%20al.%20Establishing%20a%20novel%20Fanconi%20anemia%20signaling%20pathway-associated%20prognostic%20model%20and%20tumor%20clustering%20for%20pediatric%20acute%20myeloid%20leukemia%20patients.%20Open%20Med%20(Wars.)18,%2020230847%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Chang, L. et al. Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia. <em>BMC Med Genomics</em><strong>16</strong>, 290 (2023).
</cite> [<a href="https://doi.org/10.1186/s12920-023-01730-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10652513/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37974167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chang,%20L.%20et%20al.%20Mutation%20spectrum,%20expression%20profiling,%20and%20prognosis%20evaluation%20of%20Fanconi%20anemia%20signaling%20pathway%20genes%20for%204259%20patients%20with%20myelodysplastic%20syndromes%20or%20acute%20myeloid%20leukemia.%20BMC%20Med%20Genomics16,%20290%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Mohamed, R. et al. Development of a local nomogram-based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience. <em>Med Adv.</em><strong>2</strong>, 336–348 (2024).
</cite> [<a href="https://doi.org/10.1002/med4.86" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11809524/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39931115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mohamed,%20R.%20et%20al.%20Development%20of%20a%20local%20nomogram-based%20scoring%20system%20for%20predicting%20overall%20survival%20in%20idiopathic%20pulmonary%20fibrosis:%20A%20rural%20appalachian%20experience.%20Med%20Adv.2,%20336%E2%80%93348%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Chen, G.-Q. et al. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As2O3 Exerts Dose-Dependent Dual Effects on APL Cells. <em>Blood</em><strong>89</strong>, 3345–3353 (1997).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9129041/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20G.-Q.%20et%20al.%20Use%20of%20Arsenic%20Trioxide%20(As2O3)%20in%20the%20Treatment%20of%20Acute%20Promyelocytic%20Leukemia%20(APL):%20I.%20As2O3%20Exerts%20Dose-Dependent%20Dual%20Effects%20on%20APL%20Cells.%20Blood89,%203345%E2%80%933353%20(1997)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Yang, M. H. et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. <em>Am. J. Hematol.</em><strong>93</strong>, 1467–1473 (2018).
</cite> [<a href="https://doi.org/10.1002/ajh.25271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6282847/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30160789/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang,%20M.%20H.%20et%20al.%20Multicenter%20randomized%20trial%20of%20arsenic%20trioxide%20and%20Realgar-Indigo%20naturalis%20formula%20in%20pediatric%20patients%20with%20acute%20promyelocytic%20leukemia:%20Interim%20results%20of%20the%20SCCLG-APL%20clinical%20study.%20Am.%20J.%20Hematol.93,%201467%E2%80%931473%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Garcia Spezza, E. et al. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. <em>Br. J. Haematol.</em><strong>188</strong>, 170–173 (2020).
</cite> [<a href="https://doi.org/10.1111/bjh.16364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31808943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Garcia%20Spezza,%20E.%20et%20al.%20Tolerance%20to%20arsenic%20trioxide%20combined%20with%20all-trans-retinoic%20acid%20in%20children%20with%20acute%20promyelocytic%20leukaemia%20in%20France.%20Br.%20J.%20Haematol.188,%20170%E2%80%93173%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Deka, R. R. et al. FLT3-ITD mutation does not influence survival outcome in adult acute promyelocytic leukemia patients treated with ATO and ATRA-based therapeutic regimen: Experience From a North Indian Tertiary Care Centre’. <em>Clin. Lymphoma Myeloma Leuk.</em><strong>22</strong>, 416–423 (2022).
</cite> [<a href="https://doi.org/10.1016/j.clml.2021.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34987015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deka,%20R.%20R.%20et%20al.%20FLT3-ITD%20mutation%20does%20not%20influence%20survival%20outcome%20in%20adult%20acute%20promyelocytic%20leukemia%20patients%20treated%20with%20ATO%20and%20ATRA-based%20therapeutic%20regimen:%20Experience%20From%20a%20North%20Indian%20Tertiary%20Care%20Centre%E2%80%99.%20Clin.%20Lymphoma%20Myeloma%20Leuk.22,%20416%E2%80%93423%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Estey, E. et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <em>Blood</em><strong>107</strong>, 3469–3473 (2006).
</cite> [<a href="https://doi.org/10.1182/blood-2005-10-4006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16373661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Estey,%20E.%20et%20al.%20Use%20of%20all-trans%20retinoic%20acid%20plus%20arsenic%20trioxide%20as%20an%20alternative%20to%20chemotherapy%20in%20untreated%20acute%20promyelocytic%20leukemia.%20Blood107,%203469%E2%80%933473%20(2006)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Gasparovic, L., Weiler, S., Higi, L. &amp; Burden, A. M. Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: A systematic review of the literature. <em>J. Clin. Med</em><strong>9</strong>, 3342 (2020).
</cite> [<a href="https://doi.org/10.3390/jcm9103342" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7603213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33081000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gasparovic,%20L.,%20Weiler,%20S.,%20Higi,%20L.%20&amp;%20Burden,%20A.%20M.%20Incidence%20of%20differentiation%20syndrome%20associated%20with%20treatment%20regimens%20in%20acute%20myeloid%20leukemia:%20A%20systematic%20review%20of%20the%20literature.%20J.%20Clin.%20Med9,%203342%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Montesinos, P. et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <em>Blood</em><strong>113</strong>, 775–783 (2009).
</cite> [<a href="https://doi.org/10.1182/blood-2008-07-168617" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18945964/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Montesinos,%20P.%20et%20al.%20Differentiation%20syndrome%20in%20patients%20with%20acute%20promyelocytic%20leukemia%20treated%20with%20all-trans%20retinoic%20acid%20and%20anthracycline%20chemotherapy:%20characteristics,%20outcome,%20and%20prognostic%20factors.%20Blood113,%20775%E2%80%93783%20(2009)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Tallman, M. S. et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. <em>Blood</em><strong>95</strong>, 90–95 (2000).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10607690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tallman,%20M.%20S.%20et%20al.%20Clinical%20description%20of%2044%20patients%20with%20acute%20promyelocytic%20leukemia%20who%20developed%20the%20retinoic%20acid%20syndrome.%20Blood95,%2090%E2%80%9395%20(2000)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12370879/bin/41392_2025_2353_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">supplementary material</a><sup> (2.4MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The available raw sequence data have been deposited in the Genome Sequence Archive (GSA) at the National Genomics Data Center, China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences (GSA-Human: HRA012149, HRA012104) that are publicly accessible at <a href="https://ngdc.cncb.ac.cn/gsa-human" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ngdc.cncb.ac.cn/gsa-human</a>. The datasets generated during this study are available upon request from the corresponding authors.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Signal Transduction and Targeted Therapy are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41392-025-02353-1"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41392_2025_Article_2353.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.9 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12370879/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12370879/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370879%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370879/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12370879/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12370879/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40841430/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12370879/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40841430/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12370879/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12370879/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="49g3SiwXNmHlgA90Q2CzUzoOjh9TSoSHB6i71VuOSGTRnMzrJL0T86fEfDtlSRVi">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
